Navigation Links
Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
Date:9/3/2009

the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

    For further in
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015  BioPhotas, Inc., an FDA registered medical device ... technologies to treat skin, muscle and joint conditions, today ... Fund to provide BioPhotas, flagship product, the Celluma, ... solutions.  Commenting on the alliance, ... the Celluma at the Warrior Hope and Care Center ...
(Date:3/5/2015)... HAMILTON, N.J. , March 5, 2015 /PRNewswire/ ... laboratory which specializes in high complexity, state-of-the-art, automated ... offering new Human Papillomavirus (HPV) testing which utilizes ... platforms. Each year, approximately 12,000 women ... the United States . Genital Human Papillomaviruses ...
(Date:3/5/2015)... 2015  ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... acquired the approved abbreviated new drug application ("ANDA") ... 150mg, previously marketed by Teva Pharmaceuticals.  According to ... was approximately $39 million in 2014.   ... CEO of ANI Pharmaceuticals, stated, "This acquisition further ...
Breaking Medicine Technology:BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3
... 2011 /PRNewswire/ -- MEDX, Inc., a ... the next generation T-Quest™ compact gamma camera.  The ... features expanded imaging capabilities to perform parathyroid, sentinel ... other small organ studies.  The Company also announced ...
... 6, 2011 Life Extension, a global authority on ... supplements, has launched a product featuring ChromaDex,s (CDXC.OB) pTeroPure ... food stores and natural retailers. Life Extension ... naturally found in blueberries.  Pterostilbene has been shown ...
Cached Medicine Technology:MEDX Installs Two Next Generation T-Quest™ Compact Gamma Cameras 2MEDX Installs Two Next Generation T-Quest™ Compact Gamma Cameras 3Life Extension® Launches New Product Containing ChromaDex's pTeroPure® Pterostilbene 2Life Extension® Launches New Product Containing ChromaDex's pTeroPure® Pterostilbene 3
(Date:3/5/2015)... 2015 Dr. Jonathan Glashow a board ... has been named by Castle Connolly as ... Dr. Glashow has been selected by Castle Connolly Medical ... top specialty care doctors in the tri-state metropolitan New ... program, which carefully screens and selects doctors through a ...
(Date:3/5/2015)... 2015 As a result of ... of Clearstream, LLC ’s products, services and ... line of products—led by their mPulse Hand Sanitizer—fits ... Program. , The AAPA—which represents a profession comprising ... and surgical specialties in the U.S.—advocates and educates ...
(Date:3/5/2015)... Today, Earth Source Organics (ESO) ... pollution-free electricity through a partnership with national Clean ... Arcadia Power Clean Energy Partner, ESO now meets ... requirements, joining national brands such as Whole Foods, ... Earth Source Organics joins a growing community of ...
(Date:3/5/2015)... 05, 2015 The Journal of ... a special issue devoted entirely to ... PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococci) ... reaction triggered by infections such as strep throat, ... inflammation of the child's brain. This inflammation causes ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Think it’s tough ... even tougher to get them to brush their teeth. That’s ... parents released today by Delta Dental(1) in conjunction with National ... (45 percent) say getting kids to brush their teeth is ... to do. That’s slightly higher than getting children to eat ...
Breaking Medicine News(10 mins):Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3
... Calif., March 20 A former astronaut and veteran ... director of business development for Wyle,s Integrated Science and ... joins Wyle to assist in the company,s continued growth ... and performance services to the Federal Government. He will ...
... the advancement of imaging techniques, the accuracy of preoperative ... of physical function in rectal cancer patients has become ... research article to be published on March 14, 2009 ... the prognostic factors for 5-year survival after local excision ...
... in patients with atrial fibrillation. In the current edition ... 2009; 106(10): 164-70), Thomas Bitter and his coauthors from ... breathing occurs in this form of cardiac arrythmia and ... used cardiorespiratory polygraphy to investigate whether 150 patients (110 ...
... Boehringer Ingelheim today announced that the last ... Randomized Evaluation of Long term Anticoagulant therapy (RE-LY(R)) ... safety of the oral direct thrombin inhibitor dabigatran ... international normalized ratio, INR, 2-3) for the prevention ...
... Even finding it early may not save lives, researchers say, ... that combines ultrasound and a blood test to detect CA125, ... in its early stages and often results in unnecessary surgery, ... recent study that found that these same two tests did ...
... in European UnionCorporate Highlights:- CHMP issued positive ... for treatment of peripheral neuropathic pain in ... with other medicinal products for pain- Qutenza ... for PHNUpcoming 2009 Milestones:- European commercial partnership ...
Cached Medicine News:Health News:Veteran Astronaut Joins Wyle Business Development Staff in Houston 2Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 2Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 3Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 4Health News:Combo Screening Doesn't Spot Early Ovarian Cancer 2Health News:Combo Screening Doesn't Spot Early Ovarian Cancer 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 4Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 5Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 6Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 7Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 8Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 9Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 10Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 11
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: